Ligand Acquires Ab Initio Biotherapeutics, an Antigen-Discovery Company
Ligand to Report Second Quarter 2019 Results on July 30th
Ligand Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation
ZULRESSO™ (brexanolone) CIV, a Product for Treating Postpartum Depression Using Ligand’s Captisol® in its Formulation, Launched by Sage Therapeutics
Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target
Ligand Licenses VER250840 to Cumulus Oncology
Ligand Acquires Milestone and Royalty Rights to SB206 from Novan, Inc.
Ligand Reports First Quarter 2019 Financial Results
Ligand Completes Enrollment of Phase 1 Clinical Trial of Captisol-enabled Iohexol
Ligand to Report First Quarter 2019 Results on May 2nd
Ligand to Receive Milestone and Royalties as Result of FDA Approval of Sage Therapeutics’ ZULRESSO™ (brexanolone) Injection
Ligand to Participate in Four Upcoming Investor Conferences
Ligand Provides Highlights from Today’s Analyst Day Event
